TII
3.5.2021 10:03:07 CEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of the Advanced Technology Research Council (ATRC), today announced that its Directed Energy Research Centre (DERC) has unveiled its Electromagnetic Compatibility (EMC) laboratories in Abu Dhabi, housed in a first of its kind facility in the Arab world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210503005336/en/
The facility is composed of three laboratories - an EMC semi-anechoic chamber, a pulsed power laboratory, and a low-noise emanation laboratory.
The DERC facility enables key technologies to be evaluated against electromagnetic compatibility and interference by reproducing man-made and natural electromagnetic hazards in the pulsed power and semi-anechoic chambers. The direct connection between the two chambers enables a diversity of experiments involving 100’s of kV nanosecond pulses and multi-megawatt microwaves systems. The laboratories have been designed to host different categories of equipment such as connected objects of the Internet of Things, drones and autonomous cars, telecommunications equipment, medical devices, automotive equipment, IT equipment and is fully automated for tests and measurements. A unique low-noise emanation lab has been built on DERC specifications that allow for the study of very low noises emitted by electronic systems.
Electromagnetic compatibility, or EMC, allows electronic devices that are near each other to operate without mutual interference, known as Electromagnetic Interference, EMI. The operation of electronic circuits can be compromised as they can radiate or pick up unwanted interference. Highlighting the significance of EMC is the fact that the number of devices connected wirelessly is constantly on the rise.
H.E. Faisal Al Bannai, Secretary General of ATRC , said: “The launch of these labs, which are the first and the largest in the Arab world, is aligned with the Ministry of Industry and Advanced Technology’s (MoIAT) ’Operation 300bn’ which aims to advance the industrial sector, a mandate which we fully support at ATRC as the organisation defining Abu Dhabi’s and the UAE’s research strategy across academia and industry. ATRC is investing in cutting-edge laboratories that will support in-country R&D and local industry, and encourage innovation in line with international standards. By opening these unique laboratories, non-existent before in the Arab region, we want to support innovators from prototype to a qualified system.”
DERC is pioneering research in high energy physics, and the effects of high intensity fields on different materials, systems, and environments. The Centre is committed to using its cutting-edge position in science to search for practical solutions that benefit society in diverse areas. In EMC/EMI, DERC’s research domains include modelling of the EM environment produced by human-made sources; design, production, and evaluation of antennas; innovative materials for EM shielding applications; modelling of the electro-thermal response of industrial systems; and lightning protection.
Dr. Chaouki Kasmi, Chief Researcher at Directed Energy Research Centre , said: “At DERC we support research on a wide range of topics in EMC and EMI on behalf of governments and enterprises to help create and maintain advanced electronic systems. We are excited to announce the launch of the EMC labs in Abu Dhabi. They will help in pre-qualification of electronics against Electromagnetic Compatibility and Interference Standards as well as hardening of critical infrastructures to operate safely in harsh environments.”
“Many electromagnetic compatibility standards have been introduced over the years, making EMC a key part of the electronics design process,” Dr. Kasmi said. “With standards now implemented and enforced globally, manufacturers have to ensure that new electronic products meet the relevant EMC standards.”
For more information about Technology Innovation Institute (TII), visit www.tii.ae
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005336/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom